Dr Reddy's Q1 Review: Brokerages Cut Targets After Q1 Miss; Weak US Business, Semaglutide Hit Key Triggers

How 1 sources are covering this

• NDTVCenter·3h ago

  Dr Reddy's Q1 Review: Brokerages Cut Targets After Q1 Miss; Weak US Business, Semaglutide Hit Key Triggers

  Morgan Stanley, BofA and Citi cut target prices on Dr Reddy's after a weak Q1. Here's what they said about semaglutide, margins and H2 recovery.

  Read at NDTV →